Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Zentalis Pharmaceuticals (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company, will participate in three major investor conferences in September 2025. The company, which is developing a potentially first-in-class WEE1 inhibitor for ovarian cancer and other tumor types, will present at:

• Wells Fargo Healthcare Conference (Boston) - September 4, 10:15 AM ET
• H.C. Wainwright Global Investment Conference (New York) - September 8, 2:30 PM ET
• Morgan Stanley Global Healthcare Conference (New York) - September 9, 7:00 AM ET

Live webcasts and recordings will be available on the company's website under the "Events & Presentations" section.

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that members of the management team will participate in the following upcoming investor conferences:

• 2025 Wells Fargo Healthcare Conference, Boston, MA.
  • Fireside chat, September 4, 2025, 10:15 a.m. ET.
• H.C. Wainwright 27th Annual Global Investment Conference, New York, NY.
  • Company presentation, September 8, 2025, 2:30 p.m. ET.
• Morgan Stanley 23rd Annual Global Healthcare Conference, New York, NY.
  • Fireside chat, September 9, 2025, 7:00 a.m. ET.

Access to live webcasts of the events, as well as archived recordings, will be available under the “Events & Presentations” tab on the Investors & Media section of the Company’s website.

About Zentalis Pharmaceuticals

Zentalis^® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN- c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum- resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

ZENTALIS^® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.

Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com

FAQ

When is Zentalis presenting at the Wells Fargo Healthcare Conference 2025?

Zentalis will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 4, 2025 at 10:15 AM ET in Boston, MA.

What type of drug is Zentalis (ZNTL) developing?

Zentalis is developing a potentially first-in-class and best-in-class WEE1 inhibitor targeted for patients with ovarian cancer and other tumor types.

How can investors access Zentalis (ZNTL) conference presentations in September 2025?

Investors can access live webcasts and archived recordings of the presentations through the 'Events & Presentations' tab in the Investors & Media section of Zentalis's website.

Which investor conferences is Zentalis (ZNTL) attending in September 2025?

Zentalis is attending three conferences: the Wells Fargo Healthcare Conference (Sept 4), H.C. Wainwright Global Investment Conference (Sept 8), and Morgan Stanley Global Healthcare Conference (Sept 9).